Company intelligence / Profile preview

Monument Group

Macclesfield, England, United Kingdommonumentgroup.com ↗

Ownership: Private
Development stage: Other

Overview

Monument Therapeutics is a UK-based clinical-stage biotech company applying digital biomarkers to stratify patients and accelerate the development of targeted small molecule therapies for central nervous system disorders. Their lead program, MT1988, targets cognitive impairment in schizophrenia and is currently in Phase 1 trials. Another program, MT1980, addresses neuroinflammatory conditions and postoperative cognitive dysfunction. The company’s approach aims to improve trial success rates by matching treatments to patients most likely to benefit based on brain biology.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeChemical drug (repurposed CNS-active small molecules)
Industry: Biotech

Beyond the preview

Go deeper on Monument Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monument Group.

Explore the full profile